^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    Chr t(4;14)

    11ms
    Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=70, Recruiting, Wake Forest University Health Sciences | Active, not recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    Chr t(4;14) • Chr t(14;16) • IGH translocation
    |
    lenalidomide • carfilzomib • Blenrep (belantamab mafodotin-blmf)
    11ms
    Correlation between conventional karyotype, interphase FISH and immunophenotype in risk stratification of newly diagnosed plasma cell myeloma: An observational study. (PubMed, Med J Armed Forces India)
    Immunophenotypic antigens positive and negative expressions are associated with high-risk genetic abnormalities and advanced clinical stages of PCM. IEC/2017/230, AFMC, Pune.
    Observational data • Journal • IO biomarker
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD20 (Membrane Spanning 4-Domains A1) • CD38 (CD38 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • CD28 (CD28 Molecule) • SDC1 (Syndecan 1) • CD200 (CD200 Molecule)
    |
    Chr t(11;14) • Chr t(4;14) • NCAM1 expression • PTPRC expression • NCAM1 positive
    12ms
    KTX-MMSET-001: A Study of an MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=125, Recruiting, K36 Therapeutics, Inc. | N=60 --> 125 | Trial completion date: Oct 2025 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
    |
    Chr t(4;14)
    |
    carfilzomib • pomalidomide • KTX-1001
    12ms
    High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience. (PubMed, Hemasphere)
    Nevertheless, when co-segregation was eliminated, the detrimental effect of +1q or del(1p) was no longer observed. In conclusion, this study confirms the prognostic significance of high-risk cytogenetic abnormalities in MM and highlights the importance of considering co-occurrence for accurate prognosis assessment.
    Journal • IO biomarker
    |
    CD38 (CD38 Molecule)
    |
    Chr t(4;14) • Chr t(14;16) • Chr del(1p)
    12ms
    PRISM: DARA RVD For High Risk SMM (clinicaltrials.gov)
    P2; Recruiting --> Active, not recruiting | Trial completion date: Mar 2029 --> Dec 2030 | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial completion date • Trial primary completion date • Enrollment closed
    |
    Chr t(4;14) • Chr t(14;16)
    |
    clonoSEQ
    |
    lenalidomide • bortezomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    1year
    Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL (clinicaltrials.gov)
    P1, N=20, Completed, Noah Merin | Active, not recruiting --> Completed | N=30 --> 20 | Trial completion date: Nov 2031 --> Nov 2024
    Trial completion • Enrollment change • Trial completion date
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD20 (Membrane Spanning 4-Domains A1) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD4 (CD4 Molecule) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    Chr del(17p) • Chr del(11q) • Chr t(4;14) • Chr t(14;16) • CD20 expression
    |
    Rituxan (rituximab) • bendamustine • fludarabine IV
    1year
    Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=70, Active, not recruiting, Wake Forest University Health Sciences | Trial completion date: Oct 2024 --> Nov 2032 | Trial primary completion date: Oct 2024 --> Apr 2029
    Trial completion date • Trial primary completion date • IO biomarker
    |
    Chr t(4;14) • Chr t(14;16) • IGH translocation
    |
    lenalidomide • carfilzomib • Blenrep (belantamab mafodotin-blmf)
    1year
    Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=52, Active, not recruiting, Academic and Community Cancer Research United | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Chr t(4;14) • Chr t(14;16) • Chr del(1p)
    |
    Xpovio (selinexor) • Darzalex (daratumumab) • carfilzomib
    1year
    TRIM44, a Novel Prognostic Marker, Supports the Survival of Proteasome-Resistant Multiple Myeloma Cells. (PubMed, Cells)
    Additionally, TRIM44 counters the TRIM21-mediated suppression of the antioxidant response, enhancing MM cell survival under oxidative stress. Collectively, our discoveries highlight TRIM44's significant role in MM progression and resistance to therapy, suggesting its potential value as a therapeutic target.
    Journal
    |
    SQSTM1 (Sequestosome 1) • TRIM21 (Tripartite Motif Containing 21)
    |
    Chr t(4;14)
    over1year
    The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression. (PubMed, Blood Cancer J)
    Importantly, novel potential predictors of treatment resistance were identified: NRAS mutations and the co-occurrence of t(4;14) plus FGFR3 mutations were associated with an increased risk of biological progression. In conclusion, we have carried out for the first time a molecular characterization of HR SMM patients treated with an intensive regimen, identifying genomic predictors of poor outcomes in this setting.
    Clinical Trial,Phase II • Journal
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog) • FGFR3 (Fibroblast growth factor receptor 3) • TENT5C (Terminal Nucleotidyltransferase 5C)
    |
    NRAS mutation • FGFR3 mutation • Chr t(4;14) • TENT5C mutation
    over1year
    12-C-0107: Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma (clinicaltrials.gov)
    P2, N=55, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2025 --> Jun 2028
    Trial completion date
    |
    Chr t(4;14)
    |
    lenalidomide • carfilzomib • dexamethasone injection
    over1year
    NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome. (PubMed, Blood)
    Accordingly, AK2 suppression increased sensitivity of MM cells to proteasome inhibition. These findings delineate a novel mechanism in which aberrant transfer of carbon to the epigenome creates a metabolic vulnerability, with direct therapeutic implications for t(4;14) MM.
    Journal
    |
    NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
    |
    Chr t(4;14)